Literature DB >> 12954376

Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications.

Dimitrios Tsikas1, Edzard Schwedhelm, Maria Theresia Suchy, Jonas Niemann, Frank Mathias Gutzki, Veit J Erpenbeck, Jens M Hohlfeld, Andrzej Surdacki, Jürgen C Frölich.   

Abstract

Free radical-catalysed oxidation of arachidonic acid esterified to lipids leads to the formation of the F(2)-isoprostane family which may theoretically comprise up to 64 isomers. We have previously shown that the combination of TLC and GC-tandem MS (referred to as method A) allows for the accurate and highly specific quantification of 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) in human urine. Immunoaffinity column chromatography (IAC) with immobilized antibodies raised against 8-iso-PGF(2alpha) (i.e. 15(S)-8-iso-PGF(2alpha)) has been shown by others to be highly selective and specific for this 8-iso-PGF(2alpha) isomer when quantified by GC-MS. In the present study we established IAC for urinary 8-iso-PGF(2alpha) for subsequent quantification by GC-tandem MS (referred to as method B). This method was fully validated and found to be highly accurate and precise for urinary 15(S)-8-iso-PGF(2alpha). 8-iso-PGF(2alpha) was measured in urine of 10 young healthy humans by both methods. 8-iso-PGF(2alpha) was determined to be 291+/-102 pg/mg creatinine by method A and 141+/-41 pg/mg creatinine by method B. Analysis of the combined through and wash phases of the IAC step, i.e. of the unretained compounds, by method A showed the presence of non-immunoreactive 8-iso-PGF(2alpha) at 128+/-55 pg/mg creatinine. This finding suggests that urinary 8-iso-PGF(2alpha) is heterogenous, with 15(S)-8-iso-PGF(2alpha) contributing by approximately 50%. PGF(2alpha) and other 8-iso-PGF(2alpha) isomers including 15(R)-8-iso-PGF(2alpha) are not IAC-immunoreactive and are chromatographically separated from 15(S)-8-iso-PGF(2alpha). We assume that ent-15(S)-8-iso-PGF(2alpha) is also contributing by approximately 50% to urinary 8-iso-PGF(2alpha). This finding may have methodological, mechanistic and clinical implications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954376     DOI: 10.1016/s1570-0232(03)00457-4

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

1.  Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup.

Authors:  Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-07-01       Impact factor: 3.205

2.  Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

Authors:  Ghainsom D Kom; Edzard Schwedhelm; Renke Maas; Lydia Schneider; Ralf Benndorf; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-01-03       Impact factor: 4.335

3.  Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders.

Authors:  Wolfgang Jordan; Henrik Dobrowolny; Sabine Bahn; Hans-Gert Bernstein; Tanja Brigadski; Thomas Frodl; Berend Isermann; Volkmar Lessmann; Jürgen Pilz; Andrea Rodenbeck; Kolja Schiltz; Edzard Schwedhelm; Hayrettin Tumani; Jens Wiltfang; Paul C Guest; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-02       Impact factor: 5.270

4.  Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers.

Authors:  Stefanie A Fahlbusch; Dimitrios Tsikas; Christina Mehls; Frank-Mathias Gutzki; Rainer H Böger; Jürgen C Frölich; Dirk O Stichtenoth
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

Review 5.  Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatography-tandem mass spectrometry.

Authors:  Clementina Mesaros; Seon Hwa Lee; Ian A Blair
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-17       Impact factor: 3.205

6.  Oxidative damage in clinical ischemia/reperfusion injury: a reappraisal.

Authors:  Dorottya K de Vries; Kirsten A Kortekaas; Dimitrios Tsikas; Leonie G M Wijermars; Cornelis J F van Noorden; Maria-Theresia Suchy; Christa M Cobbaert; Robert J M Klautz; Alexander F M Schaapherder; Jan H N Lindeman
Journal:  Antioxid Redox Signal       Date:  2013-03-26       Impact factor: 8.401

7.  An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.

Authors:  Hao-Jie Zhu; Bryan J Brinda; Kenneth D Chavin; Hilary J Bernstein; Kennerly S Patrick; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2013-07-08       Impact factor: 3.579

Review 8.  Mass Spectrometry in Advancement of Redox Precision Medicine.

Authors:  Xiaofei Chen; Jingyun Lee; Hanzhi Wu; Allen W Tsang; Cristina M Furdui
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 3.650

9.  Effects of paracetamol on NOS, COX, and CYP activity and on oxidative stress in healthy male subjects, rat hepatocytes, and recombinant NOS.

Authors:  Arne Trettin; Anke Böhmer; Maria-Theresia Suchy; Irmelin Probst; Ulrich Staerk; Dirk O Stichtenoth; Jürgen C Frölich; Dimitrios Tsikas
Journal:  Oxid Med Cell Longev       Date:  2014-03-31       Impact factor: 6.543

10.  The Effects of Lung Protective Ventilation or Hypercapnic Acidosis on Gas Exchange and Lung Injury in Surfactant Deficient Rabbits.

Authors:  Helmut D Hummler; Katharina Banke; Marla R Wolfson; Giuseppe Buonocore; Michael Ebsen; Wolfgang Bernhard; Dimitrios Tsikas; Hans Fuchs
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.